Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
Bangalore, India – December 2, 2025 —Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
Bangalore, India; October 22, 2025 – Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity
October 22–26, 2025, AACR-NCI-EORTC International Conference
1)Discovery and development of a highly cooperative and potent pan-KRAS degrader. 2)Identification of first-in-class paralog selective SMARCA4 degraders for treatment of hematological and prostate malignancies. 3)Discovery of highly selective, potent
April 25-30, 2025, American Association for Cancer Research
1)Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers. 2)Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis
Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma
Bengaluru & Hyderabad, India; October 8, 2024: Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective
September 30- October 3, 2024, Discovery on Target
1) Discovery and Development of pan-KRAS Degraders for Cancer Therapyn 2) Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models
Indian Council of Medical Research Signs Memorandum of Agreements with Industry and Academic Partners to Advance First-in-Human Phase 1 Clinical Trials
A key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens: Union Minister Shri J P Nadda The partnership marks a pivotal step towards establishing India’s
September 1-5, 2024, XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)
1) Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072) April 5- 10, 2024, AACR Conference
1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient